Xemilofiban [SC 54684, SC 54684A (HCl), xemlofiban], an orally active antiplatelet agent, is a glycoprotein IIb/IIIa receptor antagonist. This drug was in a phase III clinical trial in the US and Europe for the treatment of thrombosis in patients with unstable angina pectoris and acute myocardial infarction undergoing angioplasty. Because of insufficient evidence of efficacy and concerns about safety over this long of a period of treatment, these trials didn’t get the market approval. In Japan, Sankyo discontinued the development of xemilofiban for thrombosis at phase II following Searle's decision to drop the project.

Phenibut (beta-phenyl-gamma-aminobutyric acid or 4-amino-3-phenylbutyric acid) is a neuropsychotropic drug that was discovered and introduced into clinical practice in Russia in the 1960s. It has anxiolytic and nootropic (cognition enhancing) effects. It acts as a GABA-mimetic, primarily at GABA(B) receptors. Pharmacological activity of racemic phenibut relies on R-phenibut and this correlates to the binding affinity of enantiomers of phenibut to the GABAB receptor. In addition R-phenibut binds to the α2-δ subunit of voltage-dependent calcium channels. It is highly effective in treating anxiety, post-traumatic stress disorder, depression, asthenia, insomnia, alcoholism, stuttering, and vestibular disorders. It also improves mental performance (attention, memory, speed and accuracy of sensory-motor reactions), physical performance, reduces sleep disorders as well as movement and speech disorders.

Acetyl-11-keto-beta-boswellic acid (AKBA), a pentacyclic triterpene, is a component of gum resin of Boswellia serrata. It inhibits 5-lipoxygenase in a selective, enzyme directed, non-redox, and noncompetitive manner. In addition, AKBA inhibited topoisomerase I. It induces apoptosis and exerts antineoplastic properties. 5-LOXIN, a dietary supplement ingredient (Boswellia serrata extract enriched with 30% 3-O-acetyl-11-keto-beta-boswellic acid) is effective in reducing pain and improving physical functioning in osteoarthritis patients.

Thioctic acid amide is a coenzyme, which transfer acetyl and hydrogen in pyruvate deacylation oxidation process, used for pharmaceuticals. Thioctic acid amide has been described as antioxidant, preventing oxidant-mediated apoptosis. It may be used in treatment of insulin resistance by stimulating mitochondrial biogenesis. When used in combination with Alprostadil, it has shown to have a good therapeutic effect on early diabetic nephropathy. Thioctic acid amide is an ingredient of Lipochol, used for prevention of liver diseases, hepatoprotection from drugs, autointoxication.

Aniline is a toxic organic compound consisting of a phenyl group attached to an amino group. It is the prototypical aromatic amine. Aniline and its derivatives are very important for the synthesis of chemical products such as dyes, resins, and medicines. The main use of aniline is in the manufacture of precursors to polyurethane. Aniline is a carcinogen that is considered to induce tumors secondary to hemosiderosis as a consequence of methemoglobinemia. Aniline is classified as Group 3, not classifiable as to its carcinogenicity in humans (IARC, 480 1987b). Aniline occurs naturally in some foods (i.e., corn, grains, beans, and tea), but the larger source of exposure is in industrial settings. Lifetime permissible daily exposure (PDE) for aniline is 720 ug/day. Simple anilines such as aniline and monosubstituted anilines are known to disappear from the environment mainly via biodegradation.

Decanohydroxamic acid had almost no antibacterial activity. At 100 γ/ml, the acid showed growth inhibition on all the fungi tested except Monosporium apiospermum 213. The acid was found to have atropine-like, papaverine-like, anti-acetylcholine, and antihistamine actions, and a slight effect on blood (number of erythrocytes, leucocytes, and hemoglobin), but no marked effect was found on other factors. The action of this acid on the circulating system is mainly vasodilation and depression of the total carotid pressure, and no marked changes were produced in heart movement and cardiogram. A very slight irritation was observed as its local action, especially in an emulsified ointment on the skin, but not when the acid was used as a lipophilic ointment. Acute toxicity of the acid was very weak, the 2.5% Tween suspension giving the values of over 1430 mg/kg in mice by subcutaneous and intraperitoneal injection, over 7200 mg/kg in mice by oral administration.

Bismuth camphocarbonate is a complex between bismuth and camphoric acid. In 1930s intramuscular injections of bismuth camphocarbonate were used for the treatment of syphilis as an adjunct to the arsphenamines. Nowadays it is used worldwide for the treatment of bacterial infections of the mouth and throat.

Tiazotic acid is an antioxidant. As tiazotic acid morpholinium salt it is marketed under the brand names Thiotriazoline, Tiokor among others in Russia, Ukraine, Uzbekistan as the treatment of ischemic heart diseases. It is proposed to be a hepatoprotective, wound-healing and antiviral agent. A comparative international multicenter randomized trial, assessed anti-anginal anti ischemic efficacy and safety of Trimetazidine (60 mg/d) and Thiotriazoline (600 mg/d) in symptomatic patients with chronic ischemic heart disease receiving the first line therapy. The study assessed the efficacy of the two drugs on total exercise duration, time to 1-mm ST segment depression, the number of angina attacks and nitroglycerin tablets consumed amount. Both drugs have demonstrated clinical efficacy equal for all primary and secondary endpoints. Thiotriazoline was also used for the he correction of hepatotoxicity during combined chemoradiotherapy for cancer patients.

Pipemidic Acid is a quinolone antibacterial agent. It’s used in the treatment of urinary tract infections, recidive cystitis, prolongation of the therapy of pyelonephritis (prolonged therapy at patients with tendency to recidives. It belongs to DNA Gyrase inhibitor pharmacological group on the basis of mechanism of action and also classified in Antibacterial pharmacological group. Pipemidic acid is contraindicated at conditions of proved hypersensitivity, severe renal and hepatic insufficiency, cirrhosis of the liver, porphyria, diseases of the central nervous system (epilepsy and neurological conditions with low level for convulsions). Pipemidic acid is contraindicated at children and adolescents at growing phase.